aplicable disease
Download
Skip this Video
Download Presentation
Aplicable Disease

Loading in 2 Seconds...

play fullscreen
1 / 27

Aplicable Disease - PowerPoint PPT Presentation


  • 91 Views
  • Uploaded on

Aplicable Disease. World Health Organization 1997. Atherosclerosis and its consequences (ASPVD, ASCAD, ASCVD) and Cancer together are responsible for over 80% of ALL deaths in industrialized countries. “Cardiovascular Drug Therapy”1996. Metal Toxicity & Heart Disease.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Aplicable Disease' - nadine


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
world health organization 1997
World Health Organization 1997
  • Atherosclerosis and its consequences (ASPVD, ASCAD, ASCVD) and Cancer together are responsible for over 80% of ALL deaths in industrialized countries
metal toxicity heart disease
Metal Toxicity & Heart Disease
  • Chapter 175 MagnesiumEDTA chelation Martin Rubin PhD
  • EDTA acts as an anti-oxidant, anti-coagulant and decalcifies deposits.
  • 30 infusions of EDTA in a patient 14 years post MI and multi-vessel CABG. Ultrafast CT scan showed 216 calcified lesions and total calcium score of 15872. Post chelation: 118 lesions, calcium score 7970

Martin Rubin PhD

metal toxicity heart disease1
Metal Toxicity & Heart Disease
  • “EDTA chelation has an implicit advantage in that it can favorably influence all facets of the (atherosclerotic) disease development. Thus it can also provide an alternative to the combination of drugs administered to obtain a multiplicity of therapeutic effects.”

Prof. Martin Rubin

metal toxicity heart disease3
Metal Toxicity & Heart Disease

Idiopathic Dilated Cardiomyopathy

  • Hg – 22,000 x normal
  • Sb – 12,000 x normal
  • Au – 11 x normal
  • Cr – 13 x normal
  • Co – 4 x normal

Journal of American College of Cardiology, 1999

metal toxicity pvd1
Metal Toxicity & PVD
  • 79 year old woman - Presenting History
  • 1979 NIDDM and hypertension
  • 1992 Mastectomy for breast carcinoma
  • 1993 Increasing PVD
  • 1996 Left hemiplegia CVA
  • 1997 March - Severe pain in left foot at rest. Hospitalized but refused angiogram and possible amputation. Started chelation. Medications: Minidiab, Adalat, Quinine sulphate, Warfarin
slide12
Became pain-free with improved circulation after 6 weeks of chelation.
  • Discharged from the hospital vascular clinic after 6 months.
  • Maintained on monthly chelations for 4 years
metal toxicity pvd2
Metal Toxicity & PVD
  • 3 blinded controlled trials
    • Olszewer and Carter—10 patients crossover
    • Van Rij—32 patients, slight improvement, one major outlier
    • Guldagger—51% vs. 24% improved
      • Underpowered, 1/3 dropout
      • Statistical problems
      • Patients continued to smoke
      • Did not follow the standard protocol as claimed
metal toxicity vascular disease
Metal Toxicity & Vascular Disease

Multi-Centered Trial

  • 220 patients with documented vascular disease
  • Received chelation with three year follow-up
  • No deaths or MIs, 4 minor strokes
  • Symptoms improved
  • Chappell, Mitchell, Born, Ventresco, Hancke, Olszewer, van der Schaar, Blaha
metal toxicity vascular disease1
Metal Toxicity & Vascular Disease

Multi-Centered Trial

  • Compared to conventional therapies
    • Expected 31/220 angioplasties, we had 2
    • Expected 16/220 CABG, we had 6
    • Expected 15/220 MI’s, we had none
    • Expected 6/220 deaths, we had none
    • Of 185 patients with symptoms, 68% had a complete resolution
metal toxicity mi
Metal Toxicity & MI
  • Improved myocardial perfusion in patients with advanced ischemic heart disease with an integrative management program including EDTA metal binding therapy.

Ali M, et al. J Integrative Med.1997;1:7-112

metal toxicity mi1
Metal Toxicity & MI
  • Comparative study of pre- and post-chelation myocardial thallium perfusion scans showed clear, objective evidence of significant improvement in myocardial perfusion in five of six patients in whom such studies were performed
metal toxicity heart disease4
Metal Toxicity & Heart Disease
  • EDTA Chelation Therapy in Myocardial Stunning and Hibernation. Edwards D, et al. J.Adv.Med 1997;10,4:233-257
  • 5 Case Reports
  • All patients were studied using first-pass radionuclide ventriculography (RNV) All ejection fractions improved
metal toxicity heart disease5
Metal Toxicity & Heart Disease
  • Conclusion: EDTA Metal Binding Therapy clearly and convincingly reverses the condition of myocardial hibernation and possibly stunning
metal toxicity angina
Metal Toxicity & ANGINA
  • Kitchell and Meltzer-- small controlled trial, and 71% of 38 patients with disabling angina improved symptoms and exercise capacity
  • Hancke and Flytlie—69% of 253 patients improved EKG and exercise capacity, 91% of 207 patients on NTG stopped it, 58/65 on waiting list for Bypass avoided surgery
metal toxicity angina1
Metal Toxicity & ANGINA
  • Casdorph 16/18 improved ejection fractions
  • Clarke 16/20 patients assymptomatic after chelation
  • Olszewer and Carter 844 patients, 77% marked improvement, 16% good improvement
metal toxicity autism
Metal Toxicity & Autism

Important Issues of:

  • Blood Brain Barrier
  • Protein Structure
  • Total Mercury Reservoir
metal toxicity autism1
Metal Toxicity & Autism

Retrospective Study

  • 31 patients with diagnosis:
  • Autism
  • Autism Like Spectrum
  • Pervasive Developmental Delay
metal toxicity autism2
Metal Toxicity & Autism

Key To Success - Protocol

  • Trans Dermal DMPS (TD-DMPS)
  • 4 : 1 Ratio of GSH : DMPS
  • Conjugated with amino acids,
  • Delivered in a micro-encapsulated liposomal phospholipid base
metal toxicity autism3
Metal Toxicity & Autism

Retrospective Study

  • Baseline
  • 2 months
  • 4 months
  • 6 months
  • 8 months
  • 10 months
  • 12 months
  • then 4 months
metal toxicity autism4
Metal Toxicity & Autism

Retrospective Study

  • All 31 patients tested:
  • Urine Metal Toxicity & Essentials
  • Hair Metal Toxicity & Essentials
  • RBC Metal Toxicity
  • Fecal Metal Toxicity
metal toxicity autism5
Metal Toxicity & Autism

Retrospective Study

  • All 31 patients showed LITTLE or NO level of mercury on initial baseline test results
ad